IP Library Patent Application 10866593
Patent Application
App. No. 10/866,593

Method of treating functional bowel disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/866,593
Abstract

The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT 3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT 3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.

Claims (93)

1 - 62 . (canceled)

63 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.02 mg to about 200 mg per day of a compound of formula I:

or a pharmaceutically effective salt thereof to a human subject in need thereof,

wherein R 1 and R 2 independently represent hydrogen, halogen or a C 1 -C 6 alkyl group; or R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkylene group having 5 to 6 carbon atoms;

R 3 and R 4 independently represent hydrogen or a C 1 -C 6 alkyl group;

R 5 is hydrogen, C 1 -C 6 alkyl,

or —C(O)—NH—R 6

wherein m is an integer from about 1 to about 3, X is halogen and R 6 is a C 1 -C 6 alkyl group; and

Ar is a substituted or unsubstituted phenyl, 2-thienyl or 3-thienyl group; and n is 2 or 3.

64 . The method of claim 63 , wherein said pain or discomfort is pain.

65 . The method of claim 64 , wherein said pain is visceral pain.

66 . The method of claim 63 , wherein said administering is in one, two, three, or four dosages.

67 . The method of claim 63 , wherein said administering is every day.

68 . The method of claim 63 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

69 . The method of claim 63 , wherein said administering is oral.

70 . The method of claim 63 , wherein the functional bowel disorder is irritable bowel syndrome.

71 . The method of claim 70 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

72 . The method of claim 70 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

73 . The method of claim 70 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

74 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.02 mg to about 200 mg per day of a compound of formula II:

or a pharmaceutically effective salt thereof to a human subject in need thereof.

75 . The method of claim 74 , wherein said pain or discomfort is pain.

76 . The method of claim 75 , wherein said pain is visceral pain.

77 . The method of claim 74 , wherein said administering is in one, two, three, or four dosages.

78 . The method of claim 74 , wherein said administering is every day.

79 . The method of claim 74 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

80 . The method of claim 74 , wherein said administering is oral.

81 . The method of claim 74 , wherein the functional bowel disorder is irritable bowel syndrome.

82 . The method of claim 81 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

83 . The method of claim 81 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

84 . The method of claim 81 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

85 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.1 mg to about 50 mg per day of a compound of formula I:

or a pharmaceutically effective salt thereof to a human subject in need thereof,

wherein R 1 and R 2 independently represent hydrogen, halogen or a C 1 -C 6 alkyl group; or R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkylene group having 5 to 6 carbon atoms;

R 3 and R4 independently represent hydrogen or a C 1 -C 6 alkyl group;

R 5 is hydrogen, C 1 -C 6 alkyl,

or —C(O)—NH—R 6

wherein m is an integer from about 1 to about 3, X is halogen and R 6 is a C 1 -C 6 alkyl group; and

Ar is a substituted or unsubstituted phenyl, 2-thienyl or 3-thienyl group; and n is 2 or 3.

86 . The method of claim 85 , wherein said pain or discomfort is pain.

87 . The method of claim 86 , wherein said pain is visceral pain.

88 . The method of claim 85 , wherein said administering is in one, two, three, or four dosages.

89 . The method of claim 85 , wherein said administering is every day.

90 . The method of claim 85 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

91 . The method of claim 85 , wherein said administering is oral.

92 . The method of claim 85 , wherein the functional bowel disorder is irritable bowel syndrome.

93 . The method of claim 92 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

94 . The method of claim 92 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

95 . The method of claim 92 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

96 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.1 mg to about 50 mg per day of a compound of formula II:

or a pharmaceutically effective salt thereof to a human subject in need thereof.

97 . The method of claim 96 , wherein said pain or discomfort is pain.

98 . The method of claim 97 , wherein said pain is visceral pain.

99 . The method of claim 96 , wherein said administering is in one, two, three, or four dosages.

100 . The method of claim 96 , wherein said administering is every day.

101 . The method of claim 96 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

102 . The method of claim 96 , wherein said administering is oral.

103 . The method of claim 96 , wherein the functional bowel disorder is irritable bowel syndrome.

104 . The method of claim 103 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

105 . The method of claim 103 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

106 . The method of claim 103 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

107 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.5 mg to about 10 mg per day of a compound of formula I:

or a pharmaceutically effective salt thereof to a human subject in need thereof,

wherein R 1 and R 2 independently represent hydrogen, halogen or a C 1 -C 6 alkyl group; or R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkylene group having 5 to 6 carbon atoms;

R 3 and R 4 independently represent hydrogen or a C 1 -C 6 alkyl group;

R 5 is hydrogen, C 1 -C 6 alkyl,

or —C(O)—NH—R 6

wherein m is an integer from about 1 to about 3, X is halogen and R 6 is a C 1 -C 6 alkyl group; and

Ar is a substituted or unsubstituted phenyl, 2-thienyl or 3-thienyl group; and n is 2 or 3.

108 . The method of claim 107 , wherein said pain or discomfort is pain.

109 . The method of claim 108 , wherein said pain is visceral pain.

110 . The method of claim 107 , wherein said administering is in one, two, three, or four dosages.

111 . The method of claim 107 , wherein said administering is every day.

112 . The method of claim 107 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

113 . The method of claim 107 , wherein said administering is oral.

114 . The method of claim 113 , wherein 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg is administered.

115 . The method of claim 107 , wherein the functional bowel disorder is irritable bowel syndrome.

116 . The method of claim 115 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

117 . The method of claim 115 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

118 . The method of claim 115 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

119 . A method for treating pain or discomfort associated with a functional bowel disorder comprising administering from about 0.5 mg to about 10 mg per day of a compound of formula II:

or a pharmaceutically effective salt thereof to a human subject in need thereof.

120 . The method of claim 119 , wherein said pain or discomfort is pain.

121 . The method of claim 120 , wherein said pain is visceral pain.

122 . The method of claim 119 , wherein said administering is in one, two, three, or four dosages.

123 . The method of claim 119 , wherein said administering is every day.

124 . The method of claim 119 , wherein said administering is every other day, every 2 days, every 3 days, every 4 days, or every 5 days.

125 . The method of claim 119 , wherein said administering is oral.

126 . The method of claim 125 , wherein 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg is administered.

127 . The method of claim 119 , wherein the functional bowel disorder is irritable bowel syndrome.

128 . The method of claim 127 , wherein the irritable bowel syndrome is diarrhea predominant irritable bowel syndrome.

129 . The method of claim 127 , wherein the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.

130 . The method of claim 127 , wherein the irritable bowel syndrome is nonconstipated irritable bowel syndrome.

Assignments (2)
SECURITY AGREEMENT Recorded Jan 3, 2008
From: DYNOGEN PHARMACEUTICALS, INC.
To: ARACHNOVA THERAPEUTICS LIMITED
Reel/Frame 020309/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2007
From: LANDAU, STEVEN B.
To: DYNOGEN PHARMACEUTICALS, INC.
Reel/Frame 020006/0454 →